Patient Satisfaction: A Key Component in Increasing Treatment Adherence and Persistence
Oral anticoagulation (OAC) is commonly used to prevent or treat thromboembolic events in patients with conditions such as atrial fibrillation (AF) and venous thromboembolism (VTE). Until 2010, vitamin K antagonists (VKAs) were the only available type of oral anticoagulant. While VKAs are effective when used correctly, with a time in therapeutic range (TTR) of 70% or greater, they have drawbacks. The need for regular monitoring; concerns about remaining within a preset international normalized ratio (INR) range and achieving high proportion of TTR; drug, food, and alcohol interactions; and the possibility of recurrent dose adjustments may negatively affect patients' quality of life (QoL) and satisfaction with treatment. This, in turn, can have an influence on patients' adherence and persistence rates. From a clinical perspective, reduced treatment adherence and persistence can also influence physicians' willingness to prescribe OACs.
Non-VKA OACs (NOACs) have overcome some of the inherent limitations associated with VKAs, having fewer drug and food interactions, a consistent dosing regimen, and a stable pharmacokinetic profile, hence requiring less frequent monitoring (periodic renal function testing only). It is worth acknowledging that some patients may feel that regular INR monitoring and the associated contact with health professionals is preferable, as this may offer an added sense of security. However, NOACs appear to present a welcome solution to some of the practical issues associated with VKAs, which have been shown to affect treatment satisfaction.  Unsurprisingly, NOACs have been increasingly used in clinical practice, generally offering relative effectiveness, safety, and convenience compared with VKAs and leading to many prescribers switching from VKA to NOACs in real-world practice.   
The study by Katerenchuk et al in this issue of Thrombosis and Haemostasis  suggests that patients prefer NOACs over VKAs. Their systematic review and meta-analysis included four randomized controlled trials and 16 observational studies, with a total of 18,684 patients receiving OAC for either AF or VTE and demonstrated that, compared with patients treated with VKAs, those treated with NOACs reported less burden and greater treatment benefits. Participants who switched from NOACs to VKAs also reported a reduction in treatment burden and patients' global satisfaction was improved by treatment with NOACs relative to VKAs. Participants reported that NOAC treatment was less burdensome, more convenient, and more effective than VKA treatment. Overall, the systematic review by Katerenchuk and colleagues suggests that patients are more satisfied with NOAC treatment relative to VKAs, largely due to reduced treatment burden.
The systematic review and meta-analysis were robustly conducted, with study selection and data extraction performed independently by two researchers. Risk of bias was independently assessed and observational studies with high risk of bias scores were excluded from the meta-analysis. However, there was considerable heterogeneity between the included studies and outcomes relied on self-reported patient data, which introduces potential bias into the results. None of the subgroup analyses were statistically significant and there was no significant difference in patients' overall perception of NOACs versus VKAs when assessed using different satisfaction scales.
An important element of long-term anticoagulation treatment is adherence and persistence. It is hoped that greater patient satisfaction with OACs can help achieve this, as patients who are satisfied with the clinical effects and practical aspects of their medication should ideally be more willing to adhere and persist with that medication. Higher treatment satisfaction scores were associated with better adherence to OACs amongst Australian patients with AF. Reducing treatment burden can also promote better adherence and persistence. AF patients appear to rate their treatment burden as high, with one in five AF patients questioning the sustainability of their treatment as a result. Risk of non-adherence among patients with AF was significantly lower among participants taking a NOAC compared with those taking a VKA (p < 0.001). A recent Korean study exploring adherence to NOACs in a single cardiology department reported 92% adherence (measured as ≥80% prescribed doses taken).
It is important to remember that the same treatment regimen may be rated as having different treatment burdens by different patients. A patient's diagnosis, demographic factors, and comorbidities all affect how that patient interprets OAC-associated treatment burden ([Fig. 1]). In Katerenchuk et al's systematic review, there were considerable differences between the AF and VTE patient groups. Patients with VTE were an average of 15 years younger than patients with AF, and there were more men in the AF group. Furthermore, not all VTE patients required lifelong OAC treatment, which is an important distinction given that patients' adherence to OAC tends to reduce over time. A personalized approach, whereby clinicians regularly assess the impact of a specific treatment on the individual patient, is therefore needed and various tools are available to assist physicians with their assessment of patients' disease burden and treatment satisfaction levels.
However, the relationship between treatment satisfaction levels and adherence rates is complex. A French study that assessed AF patients' treatment satisfaction, adherence to treatment, and QoL scores reported mixed findings: patients' satisfaction with NOACs was significantly higher than their satisfaction with VKAs (p < 0.001). However, the greater patient satisfaction with NOACs did not translate to better medication adherence or increased QoL scores (p = 0.72 and 0.29, respectively). Among patients with VTE, it has been reported that adherence was not influenced by either OAC-associated QoL scores or practical concerns. It appears that the perceived ease of taking NOACs versus VKAs does not necessarily always translate to better adherence rates.
What does this mean for clinical practice? Given that many patients, particularly those with AF, require long-term OAC, physicians and other health care professionals need to optimize the likelihood of patient satisfaction with, and understanding of, treatment to increase medication adherence and persistence. Any treatment plan needs to be realistic, both in terms of its treatment outcomes, which should be discussed with the patient and incorporate patient's views, and treatment goals and be mindful of its practical demands of the treatment regimen on patients. Ideally, any treatment regimen would try to minimize the negative impact on a patient's QoL. Improving patients' understanding of their disease and the benefits/risk of treatment can help to minimize/offset treatment burden because appreciation of the necessity of the treatment can result in acceptance of the associated treatment burden and reduce dissatisfaction. As highlighted in the new European Society of Cardiology guidelines on the management of AF, the key to improving patient outcomes, including patient satisfaction with treatment, is a patient-centered approach to the management of chronic disease.
Received: 11 September 2020
Accepted: 11 September 2020
29 October 2020 (online)
© 2020. Thieme. All rights reserved.
Georg Thieme Verlag KG
Stuttgart · New York
- 1 Borg Xuereb C, Shaw RL, Lane DA. Patients' and health professionals' views and experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative meta-synthesis. Patient Educ Couns 2012; 88 (02) 330-337
- 2 Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010; 4: 51-60
- 3 Hohmann C, Hohnloser SH, Jacob J, Walker J, Baldus S, Pfister R. Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation. Thromb Haemost 2019; 119 (06) 971-980
- 4 Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and safety of non-vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost 2018; 118 (03) 526-538
- 5 Hohnloser SH, Basic E, Nabauer M. Changes in oral anticoagulation therapy over one year in 51,000 atrial fibrillation patients at risk for stroke: a practice-derived study. Thromb Haemost 2019; 119 (06) 882-893
- 6 Hsu CC, Hsu PF, Sung SH. et al. Is there a preferred stroke prevention strategy for diabetic patients with non-valvular atrial fibrillation? Comparing warfarin, dabigatran and rivaroxaban. Thromb Haemost 2018; 118 (01) 72-81
- 7 Katerenchuk V, Duarte GS, Martins e Pereira G. et al. Satisfaction of patients with NOACs compared to VKAs: a systematic review and meta-analysis. Thromb Haemost 2020; DOI: 10.1055/s-0040-1716752.
- 8 Hylek EM. Treatment persistence in atrial fibrillation: the next major hurdle. Thromb Haemost 2018; 118 (12) 2018-2019
- 9 Obamiro KO, Chalmers L, Lee K, Bereznicki BJ, Bereznicki LR. Adherence to oral anticoagulants in atrial fibrillation: an Australian survey. J Cardiovasc Pharmacol Ther 2018; 23 (04) 337-343
- 10 Potpara TS, Mihajlovic M, Zec N. et al. Self-reported treatment burden in patients with atrial fibrillation: quantifications, major determinants and implications for integrated holistic management of the arrhythmia. Europace 2020; DOI: 10.1093/europace/euaa210.
- 11 Banerjee A, Benedetto V, Gichuru P. et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart 2020; 106 (02) 119-126
- 12 Hwang J, Han S, Bae H-J. et al. NOAC adherence of patients with atrial fibrillation in the real world: dosing frequency matters?. Thromb Haemost 2020; 120 (02) 306-313
- 13 Raparelli V, Proietti M, Cangemi R, Lip GYH, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost 2017; 117 (02) 209-218
- 14 Arbelo E, Aktaa S, Bollman E. et al. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace 2020; DOI: 10.1093/europace/euaa253.
- 15 Aliot E, Botto GL, Crijns HJ, Kirchhof P. Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. Europace 2014; 16 (06) 787-796
- 16 Benzimra M, Bonnamour B, Duracinsky M. et al. Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation. Patient Prefer Adherence 2018; 12: 79-87
- 17 Keita I, Aubin-Auger I, Lalanne C. et al. Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adherence 2017; 11: 1625-1634
- 18 Hindricks G, Potpara TS, Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; DOI: 10.1093/eurheartj/ehaa612.